Staphylococcal and streptococcal pyrogenic toxins involved in toxic shock syndrome and related illnesses

Critical Reviews in Microbiology

Volumn 17, Issue 4, 1990, Pages 251-272

  Bohach, Gregory A ^a   Fast, David J ^b   Nelson, Robert D ^b   Schlievert, Patrick M ^b,c  

^a UNIVERSITY OF PITTSBURGH   (United States)

^b UNIVERSITY OF MINNESOTA   (United States)

^c UNIVERSITY OF IOWA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NONHUMAN; PRIORITY JOURNAL; REVIEW; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS; THEORETICAL STUDY; TOXIC SHOCK SYNDROME;

AMINO ACID SEQUENCE; ANIMAL; BACTERIAL TOXINS; BASE SEQUENCE; COMPARATIVE STUDY; ENTEROTOXINS; GENES, STRUCTURAL, BACTERIAL; HUMAN; IMMUNE TOLERANCE; IMMUNITY, CELLULAR; LYMPHOCYTE ACTIVATION; MOLECULAR SEQUENCE DATA; RABBITS; REGULATORY SEQUENCES, NUCLEIC ACID; SEQUENCE HOMOLOGY, NUCLEIC ACID; SHOCK, SEPTIC; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; STREPTOCOCCAL INFECTIONS; STREPTOCOCCUS PYOGENES; SUPPORT, NON-U.S. GOV'T; TAMPONS;

ANIMALIA; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS;

EID: 0025044872     PISSN: 1040841X     EISSN: None     Source Type: Journal    
DOI: 10.3109/10408419009105728     Document Type: Article

References (224)

1. Toxic-shock syndrome associated with phage-group-I staphylococci
2. Investigation and Laboratory Team, Toxic-shock syndrome: Epide-miologic features, recurrence, risk factors and prevention
3. Toxic-shock syndrome in menstruating women: Its association with tampon use and Staphylo-coccus aureus and the clinical features of 52 cases
4. Toxic-shock syndrome, a newly recognized disease entity: Report of 11 cases
5. Possible Kawasaki disease in a 20-year-old woman
6. Toxic-shock syndrome: A retrospective study of 25 cases from Iowa
7. Clinical manifestations of toxic-shock syndrome
8. Toxic-shock syndrome: Clinical and laboratory features in 15 patients
9. Toxic-shock syndrome in menstruating women
10. Clinical and laboratory manifestations of toxic-shock syndrome
11. Nonmenstrual toxic-shock syndrome. A review to 130 cases
12. Investigation Team, Tri-state toxic-shock syndrome study. II. Clinical and laboratory findings
13. Investigation Team, Tri-state toxic shock syndrome study: Evaluation of case definition and prevention of recurrence
14. The disease spectrum, epidemiology, and etiology of toxic-shock syndrome
15. The occurrence of Staphylococcus aureus infection with a scarlatiniform rash
16. Staphylococcic infection simulating scarlet fever
17. Scarlet-fever-like illness due to staphylococcal infection
18. Staphylococcal scarlet fever
19. Scarlet fever and necrotizing vasculitis caused by coagulase-positive hemolytic Staphylococcus aureus. phage type 85
20. Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome: Evidence for additional toxins
21. Staphylococcal enterotoxin B and toxic-shock syndrome syndrome toxin-1 are significantly associated with non-menstrual TSS
22. Involvement of staphylococcal enterotoxins in nonmenstrual toxic shock syndrome
23. Toxic shock syndrome. A newly recognized complication of influenza and influenza-like illness
24. Clinical and bacteriologic observations of a toxic shock-like syndrome due to. Streptococcus pyogenes
25. Studies of the staphylococcal causation of toxic-shock syndrome
26. Staphylococcus aureus associated with toxic shock syndrome. Phage typing and toxin capability testing
27. Genetic studies on staphylococcal strains from patients with toxic-shock syndrome
28. The biochemical and im-munological properties of toxic-shock syndrome toxin-1 (TSST-1) and association with TSS
29. Prevalence of serum antibody to staphylococcal enterotoxin F among Wisconsin residents: Implications for toxic-shock syndrome
30. Development of serum antibody to toxic shock toxin among individuals with toxic-shock syndrome in Wisconsin
31. Vaginal isolates of Staphylococcus aureus associated with toxic-shock syndrome
32. Toxin and enzyme characterization of Staphylococcus aureus isolates from patients with and without toxic-shock syndrome
33. Phenotypic distinctiveness of Staphylococcus aureus strains associated with toxic-shock syndrome
34. Epidermal toxin production by Staphylococcus aureus strains from patients with toxic-shock syndrome
35. Protein antigens from Staphylococcus aureus strains associated with toxic-shock syndrome
36. Purification and physicochemical and biological characterization of a staphylococcal pyrogenic exotoxin
37. Purification and characterization of staphylococcal pyrogenic exotoxin type B
38. Investigation Team, Tri-state toxic-shock syndrome study. I. Epidemiologic findings
39. Centers for Disease Control, Follow-up on toxic-shock syndrome
40. The relationship of tampon characteristics to menstrual toxic shock syndrome
41. Production of staphylococcal pyrogenic exotoxin type C: Influence of physical and chemical factors
42. Toxic-shock syndrome Staphylococcus aureus: Effect of tampons on toxic-shock syndrome toxin-1 production
43. Enzymic hydrolysis of tampon carboxymethylcellulose and toxic shock syndrome
44. Growth of toxic-shock syndrome strain of Staphylococcus aureus after enzymatic degradation of “Rely” tampon component
45. Hydrolysis of carboxymethylcellulose tampon material
46. Carboxymethylcellulose, tampons and staphylo-cocci
47. Control of production of toxic shock syndrome toxin-1 (TSST-1) by magnesium ion
48. Effect of magnesium on production of toxic shock syndrome toxin-1 by Staphylococcus aureus
49. Production of toxic shock syndrome toxin 1 by Staphylococcus aureus as determined by tampon disk-membrane-agar method
50. Tampon induced changes in vaginal oxygen and carbon dioxide tensions
51. Interaction of magnesium ion, oxygen tension, and temperature in the production of toxic shock syndrome toxin-1 by Staphylococcus aureus
52. Influence of focal growth conditions on the path-ogenesis of toxic shock syndrome
53. Factors affecting the regulation of staphylococcal enterotoxin B
54. Enzyme-linked immunosorbent assay for detection of type A streptococcal exotoxin: kinetics and regulation during growth of Streptococcus pyogenes
55. Streptococcal exotoxins: Biological and pathological properties
56. Erythrogenic toxins
57. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic shock syndrome
58. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates
59. Production of staphylococcal enterotoxin F and pyrogenic exotoxin C by Staphylococcus aureus isolates from toxic shock syndrome-associated sources
60. Toxic shock syndrome toxin one
61. Toxic shock syndrome toxin
62. Involvement of coagulase-negative staphylococci in toxic shock syndrome
63. Case report: toxic shock syndrome associated with TSST-1 producing coagulase-negative staphylococci
64. Evaluation of coagulase-negative staphylococci for ability to produce toxic shock syndrome toxin 1
65. Nonproduction of toxic shock syndrome toxin 1 by coagulase-negative staphylococci
66. Staphylococcal pyrogenic exotoxin type C. Further characterization
67. An enterotoxin-like protein in Staphylococcus aureus strains from patients with toxic-shock syndrome
68. Toxin involvement in toxic shock syndrome
69. Analysis of toxic shock syndrome isolates producing staphylococcal enterotoxins B and C using southern hybridization and im-munological assays
70. Novick, R. TSST-1 is encoded by a variable genetic element
71. Staphylococcal toxic shock toxin specifically binds to cultured human epithelial cells and is rapidly internalized
72. Reaction of TSST-1 with endothelium of human umbilical cord vein
73. Toxic shock syndrome: clinical, laboratory, and pathologic findings in nine fatal cases
74. Pathophysiology of staphylococcal enterotoxin, type B, (SEB) toxemia after the intravenous administration to monkeys
75. A skin test for susceptibility to scarlet fever
76. Studies on scarlet fever II. Different toxins produced by hemolytic streptococci of scarlatinal origin
77. In Preparation and properties of partially purified erythrogenic toxin B of group A streptococci
78. Host-parasite factors in group A streptococcal infections. Pyrogenic and other effects of immunologic distinct exotoxins related to scarlet fever toxins
79. The toxic shock syndrome and streptococcal pyrogenic exotoxins
80. Production of pyrogenic exotoxin by groups of streptococci: association with group A
81. Diphteria toxin: mode of action and structure
82. Cholera
83. Resolution of highly purified toxic-shock syndrome toxin 1 into two distinct proteins by isoelectric focusing
84. Purification and physicochemical properties of toxic-shock toxin
85. A simple purification method for enterotoxin F produced by Staphylococcus aureus and some properties of the toxin
86. Purification and characterization of Staphylococcus aureus FRI 1169 and 587 toxic shock syndrome exotoxins
87. The nucleotide and partial amino acid sequence of toxic shock syndrome toxin-1
88. Purification of staphylococcal enterotoxin B
89. Purification and characterization of enterotoxin C produced by Staphylococcus aureus strain 137
90. Expression of staphylococcal enterotoxin C1 in Escherichia coli
91. Modified method for production and purification of Staphylococcus aureus enterotoxin B
92. Chromatofocusing: a new method for purification of staphylococcal enterotoxins B and Cl
93. The primary structure of staphylococcal enterotoxin B. III. The cyanogen bromide peptides of reduced and aminoethylated enterotoxin B, and the complete amino acid sequence
94. The complete amino acid sequence of staphylococcal enterotoxin Cl
95. Nucleotide sequence of the enterotoxin B gene from Staphylococcus aureus
96. Nucleotide sequence of the staphylococcal enterotoxin C1 gene and relatedness to other pyrogenic toxins
97. Purification and partial characterization of a putative precursor to staphylococcal enterotoxin B
98. Fractionation of staphylococcal enterotoxin B
99. Fractionation of staphylococcal enterotoxin B by isoelectric focusing
100. Microheterogeneity of staphylococcal enterotoxin B
101. Intrinsic and chemically produced microheterogeneity of Staphylococcus aureus enterotoxin type C
102. Staphylococcal enterotoxin C. II. Some physical, immunological, and toxic properties
103. Effect of single peptide bond scission by trypsin on the structure and activity of staphylococcal enterotoxin B
104. Effect of single and double peptide bond scission by trypsin on the structure and activity of staphylococcal enterotoxin C
105. Monoclonal antibodies to staphylococcal enterotoxins B and C: Cross-reactivity and localization of epitopes on tryptic fragments
106. A purified group A streptococcal pyrogenic exotoxin. Physicochemical and biological properties including the enhancement of susceptibility to endotoxin shock
107. Further purification of group A streptococcal pyrogenic exotoxin and characterization of the purified toxin
108. Purification and characterization of group A streptococcal pyrogenic exotoxin type C
109. Purification and characterization of erythrogenic toxins. I. Investigation of erythrogenic toxin A produced by Streptococcus pyogenes strain NY-5
110. Purification et properties de la toxine erythrogene du streptocoque
111. Evidence for two molecular forms of streptococcal erythrogenic toxin. Conversion to a single form by 2-mercaptoethanol
112. Nucleotide sequence of the type A streptococcal exotoxin (erythrogenic toxin) gene from Streptococcus pyogenes bacteriophage T12
113. Streptococcal pyrogenic exotoxin type A (scarlet fever toxin) is related to Staphylococcus aureus enterotoxin B
114. Heterogeneity of group A streptococcal pyrogenic exotoxin type B
115. Cloning of the gene, speB, for streptococcal pyrogenic exotoxin type B in Escherichia coli
116. Nucleotide sequence of streptococcal pyrogenic exotoxin type C
117. Nucleotide sequence of the type A staphylococcal enterotoxin gene
118. Identification of enterotoxin E
119. Purification and some physicochemical properties of enterotoxin C, Staphylococcus aureus strain 361
120. Identification, purification, and some physicochemical properties of staphylococcal enterotoxin C3
121. Isolation of specific and common antibodies to staphylococcal enterotoxins B, C1 and C2
122. Immunologic cross-reactivity of type A streptococcal exotoxin (erythrogenic toxin) and staphylococcal enterotoxins B and C1
123. On the cross-reactivity of staphylococcal enterotoxins A, B, and Cl
124. Cross-reactions between tryptic poly-peptides of staphylococcal enterotoxins B and C1
125. Biological activities of the peptides of staphylococcal enterotoxin C formed by limited tryptic hydrolysis
126. Biological activity and complementation of the two peptides of staphylococcal enterotoxin B formed by limited tryptic hydrolysis
127. Cross-neutralization of staphylococcal and streptococcal pyr-ogenic toxins by monoclonal and polyclonal antibodies
128. Toxic shock syndrome and lysogeny in Staphylococcus aureus
129. The toxic shock syndrome exotoxin structural gene is not detectably transmitted by a prophage
130. Nucleotide sequence and functional map of pE194, a plasmid that specifies inducible resistance to macrolide, lincosamide. and streptogramin type B antibiotics
131. Cloning and expression of streptococcal pyrogenic exotoxin A and staphylococcal toxic shock syndrome toxin-1 in Bacillus subtilis
132. The genetics of bacteriophage SPO1
133. Tryptophan auxotypy associated with Staphylococcus aureus that produce toxic-shock syndrome toxin
134. Regulation of exoprotein gene expression by agr, in The Staphylococci, Jeljaszewicz
135. Regulation of exoprotein gene expression in Staphylococcus aureus by agr
136. Evidence for a coordinate transcriptional control of a alpha-toxin and protein A in Staphylococcus aureus
137. Cloning of a chromosomal locus (exp) which regulates the expression of several exoprotein genes in Staphylococcus aureus
138. Staphylococcal enterotoxin A gene is associated with a variable genetic element
139. Staphylococcal enterotoxin A is encoded by phage
140. The cloning and expression of staphylococcal enterotoxin D from Staphylococcus aureus 485
141. Hitchhiking transposons and other mobile genetic elements and site-specific recombination systems in staphylococci. Cold Spring Harbor
142. Genetic aspects of methicillin resistance and toxin production in a strain of Staphylococcus aureus
143. Isolation and characterization of a plasmid involved with enterotoxin B production in Staphylococcus aureus
144. Chromosomal locus for staphylococcal enterotoxin B
145. Genetics of staphylococcal enterotoxin B in methicillin-resistant isolates of Staphylococcus aureus
146. Plasmid-chromosomal transition of genes important in staphylococcal enterotoxin B expression
147. Structural analysis of plasmid pSN2 in Staphylococcus aureus: No involvement in enterotoxin B production
148. Molecular cloning of staphylococcal enterotoxin B gene in Escherichia coli and Staphylococcus aureus
149. Penicillinase plasmid-linked genetic determinants for enterotoxins B and C1 production in Staphylococcus aureus
150. Regulation of staphylococcal enterotoxin B
151. Regulation of staphylococcal enterotoxin B
152. Cloning and characterization of the repressor gene of the Staphylococcus aureus lactose operon
153. Transmissible toxigenicity of streptococci
154. The role of temperate bacteriophage in the production of erythrogenic toxin by group A streptococci
155. Erythrogenic toxin production by group A streptococci
156. Transfer of group A streptococcal pyrogenic exotoxin production to nontoxigenic strains by lysogenic conversion
157. Phage-host interactions and the production of type A streptococcal exotoxin in group A streptococci
158. Phage influence on the synthesis of extracellular toxins in group A streptococci
159. A physical map of the group A streptococcal pyrogenic exotoxin bacteriophage T12 genome
160. Group A streptococcal phage T12 carries the structural gene for pyrogenic exotoxin type A
161. The gene for type A streptococcal exotoxin (erythrogenic toxin) is located in bacteriophage T12
162. Bacteriophage involvement in group A streptococcal pyrogenic exotoxin A production
163. Orientation of the tox gene in the prophage of corynebacteriophage beta
164. Cloning and characterization of the gene, speC, for pyrogenic exotoxin type C from Streptococcus pyogenes
165. Production of an erythrogenic toxin (streptococcal pyrogenic exotoxin) by a nonlyso-genized group A streptococcus
166. Group A streptococcal pyrogenic exotoxin: Pyrogenicity, alteration of blood-brain barrier, and separation of sites for pyrogenicity; and enhancement of lethal endo-toxin shock
167. Biogenic amine involvement in pyrogenicity and enhancement of lethal endotoxin shock by group A streptococcal pyrogenic exotoxin
168. Pyrogenic effect of purified staph-ylococcal enterotoxin
169. Pyrogenic specificity of streptococcal exotoxins, staphylococcal enterotoxin and gram-negative endotoxin
170. Molecular basis of fever in humans
171. Tumor necrosis factor (cachectin) is an endogenous pyrogen and induces production of interleukin 1
172. Effect of antipyretics on group A streptococcal pyrogenic exotoxin fever production and ability to enhance lethal endotoxin shock
173. Nonspecific T-lymphocyte mitogenesis by pyrogenic exotoxins from group A streptococci and Staphylococcus aureus
174. Characterization of the human cellular immune response to purified group A streptococcal blastogen A
175. The mitogenic effects of endotoxin and staphylococcal enterotoxin B on mouse spleen cells and human peripheral lymphocytes
176. Evidence for cell-receptor activity in lymphocyte stimulation of staphylococcal infection
177. Relative ability of mitogens to stimulate production of interferon by lymphoid cells and to induce suppression of the in vitro immune response
178. Nonspecific and specific mitogenicity by group A streptococcal pyrogenic exotoxins
179. Specific receptor binding of staphylococcal enterotoxins by murine splenic lymphocytes
180. Alteration of immune function by staphylococcal pyrogenic exotoxin C: possible role in toxic-shock-syndrome
181. Analysis of the mitogenic effects of toxic shock toxin on human peripheral blood mononuclear cells in vitro
182. Induction of human interleukin-1 by a product of Staphylococcus aureus associated with toxic shock syndrome
183. Toxic-shock syndrome toxin-1 induced proliferation of lymphocytes: comparison of the mitogenic response of human, murine, and rabbit lymphocytes
184. Induction of human interleukin-1 by toxic-shock syndrome toxin-1
185. Interleukin-1 released by liposome-encapsulated macrophage activators
186. Induction of interleukin-1 by strains of Staphylococcus aureus from patients with nonmenstrual toxic shock syndrome
187. Toxic shock syndrome toxin-1 induces inositol phospholipid turnover, protein ki-nase C translocation, and calcium mobilization in human T lymphocytes
188. Binding of toxic-shock-syndrome toxin-1 to human peripheral blood mononuclear cells
189. Ganglioside and monosaccharide inhibition of nonspecific lymphocyte mitogenicity by group A streptococcal pyrogenic exotoxins
190. Localization of biologic functions of toxic shock syndrome toxin-1 by use of monoclonal antibodies and cyanogen bromide-generated fragments
191. Localization of a biologically important epitope on toxic-shock-syndrome toxin-1
192. Biology of interleukin-1
193. Cachectin/tumor necrosis factor production, distribution, and metabolic fate in vivo
194. Cachectin/tumor necrosis factor induces lethal shock and stress hormone responses in the dog
195. Synergistic induction of Interleukin-1 by endotoxin and toxic shock syndrome toxin-1 using rat macrophages
196. Binding of staphylococcal enterotoxin A (SEA) with human splenic lymphocytes
197. Non-purulent response to toxic shock syndrome toxin-1 producing Staphylococcus aureus: relationship to toxin-stimulated production of tumor necrosis factor
198. Alteration of clearance function by group A streptococcal pyrogenic exotoxin and its relation to suppression of the antibody response
199. Suppression of the antibody response by group A streptococcal pyrogenic exotoxin and characterization of the cells involved
200. The effect of staphylococcal enterotoxins on the primary in vitro immune response
201. Activation of murine T-suppressor lymphocytes by group A streptococcal and staphylococcal pyrogenic exotoxins
202. Suppression of immuno-globulin-secreting cells from human peripheral blood by toxic-shock-syndrome toxin-1
203. Im-balanced serum IgG subclass pattern in toxic shock syndrome patients: deficiency of specific IgG1 and IgG4 subclass antibodies to toxic shock syndrome toxin-1
204. IFN-rcgulates the isotypes of Ig secreted during in vivo humoral immune responses
205. Biological effects of staphylococcal enterotoxin A on human peripheral lymphocytes
206. Enhancement of host susceptibility to lethal endo-toxin shock by staphylococcal pyrogenic exotoxin type C
207. Evidence for involvement of endotoxin in toxic shock syndrome
208. Reinterpre-tation of the Dick test: role of group A streptococcal pyrogenic exo-toxins
209. Clearance of endotoxin from blood of rabbits injected with staphylococcal toxic shock syndrome toxin-1
210. Inhibition of ribonucleic acid synthesis by group A streptococcal pyrogenic ex-otoxin
211. Enhancement of bacterial endotoxin lethality by staphylococcal enterotoxin
212. Toxicity of staphylococcal toxic shock syndrome toxin-1 in rabbits
213. Possible endo-toxemia in rabbits after intravenous injection of Staphylococcus aureus enterotoxin B
214. Protection against staphylococcal pyrogenic exotoxin C enhanced endotoxin lethality with methyl prednisolone and immunoglobulin G
215. Enhancement of endotoxin-induced isolated renal tubular cell injury by toxic-shock syndrome toxin-1
216. Effects of Staphylococcus aureus enterotoxin F on human neutrophil metabolism
217. A rabbit model of toxic shock syndrome: Clinico-pathological features
218. Acquired ability of Staphylococcus aureus to produce toxic shock-associated protein and resulting illness in a rabbit model
219. Expression of the cloned toxic shock syndrome toxin 1 gene (tst) in vivo with a rabbit uterine model
220. A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1
221. Biological and immunological properties of the carboxyl terminus of staphylococcal enterotoxin C1
222. Reappearance of scarlet fever toxin A among streptococci in the Rocky Mountain West: Association with tissue invasion and the toxic-shock-like syndrome